Stirling reports positive preliminary trial results
Tuesday, 30 November, 2004
Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.
Final results from the trial, which was conducted in the US by the USDA's Swine Research Unit, will be released early in 2005. The trial was designed to measure physiological and behavioural parameters including weight gain, feed conversion, increase in lean meat and decrease in fat content.
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
